Effect of oral anticoagulants on the outcome of faecal immunochemical test

L Bujanda*,1, C Sarasqueta2, Á Lanas3, E Quintero4, J Cubiella5, V Hernandez6, J D Morillas7, T Perez-Fernández8, D Salas9, M Andreu10, F Carballo11, X Bessa10, I Portillo12, R Jover13, F Balaguer14, A Cosme1 and A Castells14 on behalf of COLONPREV study investigators15

1Department of Gastroenterology, Hospital Universitario Donostia, Instituto Biodonostia, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain; 2Hospital Universitario Donostia, Instituto Biodonostia, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), San Sebastián, Spain; 3Department of Gastroenterology, University of Zaragoza, IIS Aragón, CIBERehd, Zaragoza, Spain; 4Department of Gastroenterology, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain; 5Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain; 6Servicio de Aparato Digestivo, Complejo Hospitalario Universitario de Vigo, Vigo, Spain; 7Department of Gastroenterology, Hospital Clínico San Carlos, Madrid, Spain; 8Department of Gastroenterology, Hospital Fundación Alcorcón, Madrid, Spain; 9Programa de Cribado de Cáncer Colorectal, Dirección General de Salud Pública, Conselleria de Sanitat, Valencia, Spain; 10Department of Gastroenterology, Hospital del Mar, IMIM, Barcelona, Catalonia, Spain; 11Unidad de Gestión Clínica de Digestivo, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; 12Centro Coordinador del Programa de Cribado Cáncer Colorrectal, Organización Central de Osakidetza-Servicio Vasco de Salud, Bilbao, Spain; 13Department of Gastroenterology, Hospital General Universitario de Alicante, Alicante, Spain and 14Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain

Background: We aimed to evaluate whether oral anticoagulants (OACs) alter faecal immunochemical test (FIT) performance in average-risk colorectal cancer (CRC) screening.

Methods: Individuals aged 50–69 years were invited to receive one FIT sample (cutoff 75 ng ml−1) between November 2008 and June 2011.

Results: Faecal immunochemical test was positive in 9.3% (21 out of 224) of users of OAC and 6.2% (365 out of 5821) of non-users (P-trend = 0.07). The positive predictive value (PPV) for advanced neoplasia (AN) in non-users was 50.4% vs 47.6% in users (odds ratio, 0.70; 95% CI, 0.3–1.8; P = 0.5). The PPV for AN in OAC users more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4–10.8; P = 0.4).

Conclusions: Oral anticoagulant did not significantly modify the PPV for AN in this population-based colorectal screening program. The detection rate of advanced adenoma was higher in the combination OAC more antiplatelets.

The faecal immunochemical test (FIT) is one of the tests recommended by different societies for colorectal cancer (CRC) screening in average-risk populations (Levin et al, 2008). Faecal immunochemical test is performed annually or biennially after age 50. In a recently published population-based, randomised trial, FIT detected an equivalent number of CRC as colonoscopy in the first CRC screening round (Quintero et al, 2012). There is no consensus among experts about whether oral anticoagulants (OACs) alone or in combination with antiplatelet drugs should be suspended before stool collection for FIT.

*Correspondence: Dr L Bujanda; E-mail: medik@telefonica.net

15All investigators are listed in the Supplementary note.

Received 17 September 2013; revised 20 December 2013; accepted 8 January 2014; published online 4 February 2014
Previous studies from our group have observed aspirin and antiplatelets should not be stopped before FIT, as these drugs do not diminish the positive predictive value (PPV) for advanced neoplasia (AN; Bujanda et al, 2013).

The objective of this study was to determine whether the use of OAC, alone or in combination with antiplatelet drugs, affects the positivity and detection rates for AN in average-risk subjects undergoing CRC screening.

### MATERIALS AND METHODS

#### Study design.
We performed a post hoc analysis of subjects assigned to the FIT arm of the COLONPREV trial, a randomised controlled study aimed at comparing one-time colonoscopy vs biennial FIT for the reduction of CRC-related mortality at 10 years in an average-risk population. The study, described in detail elsewhere (Quintero et al, 2012), started in November 2008 and the first round was completed in June 2011. Subjects agreeing to participate in the study received an appointment to the local screening office. The data manager conducted a questionnaire (face to face) about taking drugs (type, dose and frequency). Patients usually have a list of the drugs they take. At the time of the interview, data manager explained how to make the FIT without stopping any medication.

Faecal immunochemical test strategy consisted of a single sample using the automated semiquantitative OC-Sensor kit (Eiken Chemical Co., Tokyo, Japan), without any specific diet or medication limitations. Patients with \( \geq 75\, \text{ng haemoglobin per ml of buffer solution (} \geq 15 \mu\text{g of haemoglobin per gram of faeces)} \) were invited for a colonoscopy (Fraser et al, 2012).

Within this cohort, we defined the ‘users’ as those reporting chronic use of OAC (acenocoumarol), alone or in combination with antiplatelet drugs. Antiplatelet drugs were aspirin \( \leq 300\, \text{mg day}^{-1} \) or clopidogrel. The non-users group consisted of subjects not taking any of these drugs, either chronically or sporadically, within 30 days of testing. Patients taking these drugs intermittently or sporadically within 30 days of testing were excluded from the analysis. Individuals taking new anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) or non-steroidal anti-inflammatory drugs were also excluded. No change in medication before stool collection was recommended.

Adenomas \( \geq 10\, \text{mm in size, with villous architecture, high-grade dysplasia or intramuscosal carcinoma were classified as advanced adenomas. Advanced neoplasia was defined as advanced adenoma or invasive cancer. Non-AN (NAN) were classified as the presence of one or two small adenomas <10 mm. Invasive cancer was considered to exist when malignant cells were observed beyond the muscularis mucosa. A specific program was designed to ensure the quality of the whole process (Jover et al, 2012; Quintero et al, 2012).} \)

#### Statistical analysis.
Chi-square test and/or Fisher test was used to compare categorical variables across the groups and one-way ANOVA was used to compare continuous variables. Faecal haemoglobin measurements are presented as medians and compared using the non-parametric Kruskal–Wallis test. The positivity rate and the PPV was calculated for the users and non-users group.

#### RESULTS

Postal invitations to undergo FIT were sent to a total of 28696 individuals, with a mean age of 59.5 \pm 5.5 years, 47% were men. Of them 1054 (3.6%) invitations were returned unanswered. In addition, 1043 (3.6%) were excluded either permanently or temporarily. The eligible population consisted of 26599 people.

A total of 10611 (36.9%) individuals returned the test and 6045 (56.9%) fulfilled the questionnaire and reported adequate information on the use of OAC (Figure 1). Mean age was 59.5 \pm 5.6 years and 2803 (46%) were men. Of the 6045 participants, 5821 (96.3%) reported not using any of these drugs (non-users group), and 224 (3.7%) reported taking OAC alone or in combination with antiplatelet drugs before testing (users group). In the users group, 164 individuals reported taking OAC alone and 60 OAC in combination with antiplatelet drugs. As expected, more men were taking these drugs than women and age was higher in those taking antiplatelet drugs than in non-users (Table 1). There were no differences in the type or the location of lesions (CRC, AN and NAN) between users and non-users group.

Faecal immunochemical test was positive for occult blood in 386 of 6045 participants (6.3%). Of the 386 people with positive test, colonoscopy was normal in 124 (32%) cases, whereas 20 (5%) had CRC, 174 (45%) AA and 68 (18%) NAN. Tumour staging of identified lesions (FIT: stage I in 16; stage II in 2 and stage III in 2).

Faecal immunochemical test was positive in (21 out of 224) 9.3% of the users group and (365 out of 5821) 6.2% in the non-users group (P-trend = 0.07; Table 2). The number of AN found in the OAC more antiplatelet therapy users not differ significantly with non-users (Table 3). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4–10.8; P = 0.4). Median haemoglobin concentration detected in the stool did not differ significantly between non-users and users (285 ng ml\(^{-1}\) vs 502 ng ml\(^{-1}\); P-trend = 0.2).

The PPV for AN in the non-user group was 50.4% and 47.6% (Table 4). The PPV for NAN was 50.4% (184 out of 365), 30.8% (4 out of 13) and 75% (6 out of 8), in the non-users, OAC, and OAC in combination with other drugs respectively, without significant differences (P = 0.2).

#### DISCUSSION

The number of people with long-term OAC therapy is increasing. In 2006, 4% of the population taking OAC (equal to our study) and 9% of those over 65 years (Dossett et al, 2011). Patients with prosthetic heart valves, chronic or paroxysmal atrial fibrillation, recurrent deep venous thrombosis, hypercoagulable diseases, and vascular diseases are currently maintained on long-term anticoagulants. Anticoagulation is mandatory to reduce the risk of
thromboembolism, but at the same time the therapy increases the risk of bleeding.

In our study, the OAC alone or in combination with antiplatelet drugs showed increased FIT positivity without increasing the false positivity rate. The rate of positive for control, OAC and the combination were 6.2%, 7.9% and 13.3%, respectively. There were no statistically significant differences in the PPV for AN in comparing with non-users. Only three studies (Levi et al, 2009; Sawhney et al, 2010; Mandelli et al, 2011) have analysed the effect of OAC on the FIT performance. A study (Levi et al, 2009) includes 16 individuals taking warfarin, nevertheless, concluded that anticoagulants were associated increased sensitivity with no change in specificity for NA. Another study (Mandelli et al, 2011) examines 53 patients taking OAC with positive FIT and compared with 106 controls (positive FIT without OAC). Advanced neoplasia was detected in 28.3% of cases and 34.9% of controls without statistically significant difference. The third study (Sawhney et al, 2010) concluded that OAC reduces the PPV for AN compared with controls (20% in OAC vs 30% in controls). However, this study has some differences with our research, the number of patients taking anticoagulants was lower (85 individuals), the test used was the haemoccult II and patients were not a screening program. In the latter study, the percentage of patients with CRC and AN was low, 3.1% and 24%, respectively, probably due to the test performed. In our study, the proportion of CRC and AN in patients with positive FIT was 5% and 50%, respectively. Our data suggest that combination therapy increases bleeding of AN facilitating their detection with FIT. Another advantage by not suspending the anticoagulant is that it can also help increase public participation in CRC screening since discontinuation has been linked to increased risk of stroke and other adverse cardiovascular events (Blacker et al, 2003).

This study has certain strengths. First, its database was that of a prospective clinical trial without selection bias, which should minimise confounders for the detection of AA and AN. Second, the number of cases analysed is higher than that reported to date (Levi et al, 2009; Sawhney et al, 2010; Mandelli et al, 2011). Third, the original trial was performed with FIT, unlike others which have used the guaiac faecal occult blood test (Sawhney et al, 2010). Finally, the study was performed in asymptomatic individuals, in contrast to other studies (Levi et al, 2009; Sawhney et al, 2010).

The study also has some limitations. First, colonoscopy was not performed on patients with a negative FIT, so we were not able to determine the influence OAC drugs may have had on the negative predictive value of FIT. Second, no information was collected on prothrombin time-international normalised ratio at the time of the FIT. Third, other factors such as history of gastrointestinal bleeding or presence of serious comorbid conditions (acute myocardial infarction, renal insufficiency and severe anaemia), can interfere results. Finally, the number of patients in the combined group (OAC more antiplatelets) with positive FIT and AN were low.

Table 1. Characteristics of individuals included in the study

|                   | Users group (n = 224) | Non-users group (n = 5821) | P-value |
|-------------------|-----------------------|---------------------------|---------|
| Positive FIT      | 21 (9.3%)             | 365 (6.2%)                | 0.07    |
| Age (years-old)   | 62.2 (s.d.: 5.6)      | 59.4 (s.d.: 5.5)          | <0.001  |
| Male sex (%)      | 140 (54.1%)           | 2663 (46%)                | 0.003   |
| Proton pump inhibitor | 134 (60%)         | 874 (15%)                 | <0.001  |

Cardiac disease

|                                | Users group (n = 224) | Non-users group (n = 5821) | P-value |
|--------------------------------|-----------------------|---------------------------|---------|
| Valve prosthesis              | 28 (12.5%)            | —                         | <0.001  |
| Atrial fibrillation           | 140 (62.5%)           | 128 (22.2%)               |         |
| Prevention thromboembolism    | 42 (18.75%)           | —                         |         |
| Others                         | 14 (6.5%)             | —                         |         |
| Ischemic stroke-heart         | 67 (30%)              | 320 (5.5%)                | <0.001  |

Results of colonoscopy

|                                | Users group (n = 224) | Non-users group (n = 5821) | P-value |
|--------------------------------|-----------------------|---------------------------|---------|
| Cancer                         | 1 (4.8%)              | 19 (5.2%)                 | 0.5     |
| Advanced adenoma               | 9 (42.9%)             | 165 (45.2%)               |         |
| Non-advanced adenoma           | 4 (19%)               | 64 (17.5%)                |         |
| Normal                         | 7 (33.3%)             | 117 (32.1%)               |         |

Location of lesions

| Location of lesions | Users group (n = 224) | Non-users group (n = 5821) | P-value |
|---------------------|-----------------------|---------------------------|---------|
| Distal              | 10 (71.5%)            | 180 (72.6%)               | 0.5     |
| Proximal            | 4 (28.5%)             | 68 (27.4%)                |         |

Table 2. Comparison of FIT-positive rate between OACs non-user and user groups

|                                | Individuels + FIT, no. (%) | OR* | 95% CI | P-value |
|--------------------------------|-----------------------------|-----|-------|---------|
| Non-users group                | 5821                        | 365 (6.2) | 1 (Ref.) |         |
| Users group                    | 224                         | 21 (9.3) | 1.3   | 0.8–2.1 | 0.3     |
| OAC                            | 164                         | 13 (7.9) | 1.15  | 0.6–2.1 | 0.6     |
| OAC + others                   | 60                          | 8 (13.3) | 1.8   | 0.8–3.9 | 0.2     |

Abbreviations: CI = confidence interval; FIT = faecal immunochemical test; OAC = oral anticoagulant; OR = odds ratio; Others = aspirin <300 mg day−1 or clopidogrel.

*OR, comparing users with non-users, adjusted for age and sex.

Table 3. AN found in each group

|                                | Individuels | AN, (%) | OR* | 95% CI | P-value |
|--------------------------------|-------------|---------|-----|-------|---------|
| Non-users group                | 5821        | 184 (3.2) | 1 (Ref.) |       |
| Users group                    | 224         | 10 (4.5) | 1.1 | 0.5–2.1 | 0.8    |
| OAC                            | 164         | 4 (2.4) | 0.6 | 0.2–1.7 | 0.4    |
| OAC + others                   | 60          | 6 (10)  | 2.3 | 0.9–5.9 | 0.08   |

Abbreviations: AN = advanced neoplasm; CI = confidence interval; FIT = faecal immunochemical test; OAC = oral anticoagulant; OR = odds ratio; Others = aspirin <300 mg day−1 or clopidogrel.

*OR, comparing users with non-users, adjusted for age and sex.

Table 4. Positive predictive value of faecal immunochemical test for AN according to group and user group

|                                | FIT positive | PPV for AN, no. (%) | OR | 95% CI | P-value |
|--------------------------------|--------------|---------------------|----|-------|---------|
| Non-users group                | 365          | 184 (50.4)          | 1.0|       |         |
| Users group                    | 21           | 10 (47.6)           | 0.7| 0.3–1.8| 0.5    |
| OAC                            | 13           | 4 (30.8)            | 0.4| 0.1–1.3| 0.14   |
| OAC + others                   | 8            | 8 (75)              | 2.0| 0.4–10.8| 0.4    |

Abbreviations: AN = advanced neoplasm; CI = confidence interval; FIT = faecal immunochemical test; OAC = oral anticoagulant; OR = odds ratio; Others = aspirin <300 mg day−1 or clopidogrel; PPV = positive predictive value.

*OR, comparing users with non-users, adjusted for age and sex.

The study also has some limitations. First, colonoscopy was not performed on patients with a negative FIT, so we were not able to determine the influence OAC drugs may have had on the negative predictive value of FIT. Second, no information was collected on prothrombin time-international normalised ratio at the time of the FIT. Third, other factors such as history of gastrointestinal bleeding or presence of serious comorbid conditions (acute myocardial infarction, renal insufficiency and severe anaemia), can interfere results. Finally, the number of patients in the combined group (OAC more antiplatelets) with positive FIT and AN were low.
In conclusion, we found that the anticoagulants alone or in combination with antiplatelet drugs did not reduce the PPV of FIT for AN. This suggests that OAC therapy should not be discontinued before stool collection for FIT.

ACKNOWLEDGEMENTS

This work was supported by grants from Asociación Española contra el Cáncer (Fundación Científica y Junta de Barcelona), the Instituto de Salud Carlos III (PI08/90717) and Agencia de Gestión d’Ajuts Universitaris i de Recerca (2009SGR849). Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by Instituto de Salud Carlos III. In the Basque Country, the study received additional support with grants from Obra Social de Kutxa, Diputación Foral de Gipuzkoa (DFG 07/5), Departamento de Sanidad del Gobierno Vasco, EITB-Maratoia (BIO 07/CA/19) and the Acción Transversal contra el Cáncer del CIBERehd (2008). In Galicia, this work was supported by Dirección Xeral de Innovación e Xestión da Saúde Pública, Conselleria de Sanidade, Xunta de Galicia. OC-Micro instruments and FITs were kindly provided by Eiken Chemical Co., Ltd, Japan, and its Spanish representatives, Palex Medical and Biogen; none of them were involved in the design of study or in the analysis or interpretation of results.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

LB, AL, EQ and A Castells developed the study concept and design and drafted the manuscript. EQ, A Castells, JC, VH, JDM, TP-F, DS, MA, FC, XB, IP, RJ, FB, A Cosme and A Castells acquired the clinical data, designed and analysed the database and interpreted the data. LB and CS carried out the statistical analysis of data and contributed to the interpretation of data. All had the opportunity to revise the manuscript.

REFERENCES

Blacker DJ, Wijdicks EF, Mc Clelland RL. (2003) Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 61: 964–968.

Bujanda L, Lanas A, Quintero E, Castells A, Sarasqueta C, Cubiella J, Hernandez V, Morillas JD, Perez-Fernandez T, Salas D, Andreu M, Carballo F, Bessa X, Cosme A, Jover R. COLONPREV Study Investigators (2013) Effect of aspirin and antiplatelet drugs on the outcome of fecal immunochemical test. Mayo Clin Proc 88: 683–689.

Dossett LA, Riesel JN, Griffin MR, Cotton BA (2011) Prevalence and implications of preinjury warfarin use. Arch Surg 146: 565–570.

Fraser CG, Allison JL, Halloran SP, Young GP; Expert Working Group on Fecal Immunochromical Tests for Hemoglobin: Colorectal Cancer Screening Committee; World Endoscopy Organization (2012) A proposal to standardize reporting units for fecal immunochromical tests for hemoglobin. J Natl Cancer Inst 104: 810–814.

Jover R, Herráiz M, Alarcón O, Brullet E, Bujanda L, Bustamante M, Campo R, Carreño R, Castells A, Cubiella J, García-Iglesias P, Hervás AJ, Menchón P, Ono A, Panadés A, Parra-Blanco A, Pellisé M, Ponce M, Quintero E, Reñé JM, Sánchez del Río A, Seoane A, Serradasanferm A, Soriano Izquierdo A, Vázquez Sequeiros E. Spanish Society of Gastroenterology; Spanish Society of Gastrointestinal Endoscopy Working Group (2012) Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 44: 444–451.

Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Mace E, Birkenfeld S, Lieberman N, Klang S, Niv Y (2009) Sensitivity, but not specificity, of a quantitative immunochromical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs and anticoagulants. Am J Gastroenterol 104: 933–938.

Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorsen A, Winawer SJ. American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134: 1570–1595.

Mandelli G, Radaelli F, Paggi S, Terreni N Gola G, Gramegna M, Bonaffini A, Terruzzi V (2011) Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol 23: 323–326.

Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradasanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A. COLONPREV Study Investigators (2012) Colonoscopy versus fecal immunochemical test in colorectal cancer screening. N Engl J Med 366: 697–706.

Sawhney MS, McDougall H, Nelson DB, Bond JH (2010) Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 55: 1637–1642.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)